<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02578069</url>
  </required_header>
  <id_info>
    <org_study_id>NOVA-001</org_study_id>
    <nct_id>NCT02578069</nct_id>
  </id_info>
  <brief_title>First-in-man Trial Evaluating the Safety and Efficacy of the NOVA Intracranial Stent (NOVA Trial)</brief_title>
  <acronym>NOVA</acronym>
  <official_title>A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Efficacy of the NOVA Sirolimus Eluting Stent Versus the Apollo Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sino Medical Sciences Technology Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sino Medical Sciences Technology Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, randomized 1:1 single blind trial using NOVA sirolimus eluting&#xD;
      stent versus Apollo bare metal stent conducted in approximately 15 interventional neurology&#xD;
      centers in China. The study was sponsored by Sino Medical Sciences Technology Inc.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll 264 subjects overall in two groups (randomized 1:1). The study&#xD;
      follow-up will occur at 1, 6 and 12 months post-stent implantation. All patients will undergo&#xD;
      angiography assessment (DSA/CTA) at 12 months follow-up. Angiography assessment will be&#xD;
      performed at baseline (pre- and post-procedure) and 12 months follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 27, 2015</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In stent restenosis rate (&gt; 50% restenosis)</measure>
    <time_frame>12 months post-procedure</time_frame>
    <description>Angiography assessment at 12 months post-procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stroke and death events</measure>
    <time_frame>within 30 days after stenting</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel ischemic stroke event</measure>
    <time_frame>between 30 days and 1 year post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute procedural success rate (stenosis &lt; 30%)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel stroke or death events</measure>
    <time_frame>within 30 days after stenting</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-target vessels ischemic stroke event</measure>
    <time_frame>between 30 days and 1 year post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent ischemic stroke in the involved vascular area</measure>
    <time_frame>between 30 days and 1 year post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral parenchyma hemorrhage, subarachnoid hemorrhage and intraventricular bleeding events</measure>
    <time_frame>between 30 days and 1 year post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death event</measure>
    <time_frame>between 30 days and 1 year post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient ischemic attack event</measure>
    <time_frame>within 1 year post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institutes of Health Stroke Scale (NIHSS) evaluation</measure>
    <time_frame>at 1 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modulate RANK score （mRS）evaluation</measure>
    <time_frame>at 1 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA) evaluation</measure>
    <time_frame>at 1 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D score evaluation</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">272</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NOVA Intracranial sirolimus eluting stent system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Apollo Intracranial stent system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NOVA Intracranial Sirolimus Eluting Stent System</intervention_name>
    <description>A sirolimus eluting intracranial stent system with polylactic-co-glycolic acid (PLGA) biodegradable drug carrier and electro-grated polybutyl methacrylate (PBMA) base coating. The stent platform is made of 316L stainless steel.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Apollo Intracranial Stent System</intervention_name>
    <description>A 316L stainless steel balloon-expandable intracranial stent system</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 to 75 years of age;&#xD;
&#xD;
          2. Primary or recurrent symptomatic intracranial arteriostenosis through the internal&#xD;
             medicine treatment (i.e. stroke or transient ischemic attack within 90 days during the&#xD;
             treatment with at least one anti-thrombotic drugs and vascular risk factor&#xD;
             intervention e.g. hypertensors for hypertension and hypolipidemics for&#xD;
             hyperlipidemia);&#xD;
&#xD;
          3. No transient ischemic attack (TIA) or ischemic stroke occurred within 2 weeks prior to&#xD;
             stenting procedure;&#xD;
&#xD;
          4. ≥70% stenosis of intracranial responsible vessel under the DSA angiography (as judged&#xD;
             through the WASID method);&#xD;
&#xD;
          5. Poor blood circulation in the side branch of responsible vessel area under the&#xD;
             angiography within one week prior to stenting procedure:&#xD;
&#xD;
             Score of blood circulation in the side branch under the DSA &lt;3 or blood flow rate peak&#xD;
             ≥200cm/s at the systolic phase under the transcranial doppler ultrasonic examination&#xD;
             (TCD); or no apparent side branch compensation in the responsible vessel area under&#xD;
             CTA or score of blood circulation in the side branch under the CTA &lt;2;&#xD;
&#xD;
          6. The target lesion reference diameter must be visually estimated to be ≥2.0 mm in&#xD;
             diameter, and lesion length must be &lt;15 mm; no lesion observed in the distal vessel;&#xD;
&#xD;
          7. Atherosclerosis lesions;&#xD;
&#xD;
          8. mRS &lt; 3;&#xD;
&#xD;
          9. Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. &gt;70% intracranial large-vessel stenosis beyond the responsible vessel;&#xD;
&#xD;
          2. &gt;70% stenosis observed at the intracranial large-vessel distal to the responsible&#xD;
             vessel or &gt;70% stenosis observed at the intracranial/extracranial large-vessel&#xD;
             proximal to the responsible vessel;&#xD;
&#xD;
          3. Acute ischemic stroke within 3 weeks;&#xD;
&#xD;
          4. Obstruction of perforating branch artery under the skull MRI;&#xD;
&#xD;
          5. Intracranial hemorrhage in the angiopathic area within 6 weeks;&#xD;
&#xD;
          6. Patient was treated by thrombolytic therapy within 24 hours;&#xD;
&#xD;
          7. Patients underwent surgery within 30 days or plan for surgery within 3 months&#xD;
             post-stenting procedure;&#xD;
&#xD;
          8. Severe calcified lesions;&#xD;
&#xD;
          9. Patients have been treated by intracranial/extracranial stenting procedures prior to&#xD;
             this study;&#xD;
&#xD;
         10. Nonatherosclerosis lesions;&#xD;
&#xD;
         11. Patients with potential sources for cardiac embolism;&#xD;
&#xD;
         12. Concomitant intracranial tumor, aneurysm or intracranial arteriovenous malformation;&#xD;
&#xD;
         13. Known hypersensitivity or contraindication to aspirin, heparin, antiplatelet&#xD;
             medication specified for use in the study, sirolimus, poly(lactic-co-glycolic acid)&#xD;
             polymers, or poly(n-butyl methacrylate);&#xD;
&#xD;
         14. Hemoglobin &lt;100g/L, platelet count &lt;100,000 cells/mm3, International normalized ratio&#xD;
             (INR) &gt;1.5 (irreversible) or uncorrectable hemorrhagic factors;&#xD;
&#xD;
         15. Serious neural dysfunction due to the responsible angiopathy as the sequel of cerebral&#xD;
             infarction (mRS≥3);&#xD;
&#xD;
         16. Known liver or renal insufficiency (ALT&gt; 3x upper limit or AST &gt; 3x upper limit,&#xD;
             creatinine &gt; 1.5x upper limit);&#xD;
&#xD;
         17. Life expectancy &lt; 2 years;&#xD;
&#xD;
         18. Pregnant/lactating female patients;&#xD;
&#xD;
         19. Patients with cognitive impairment or mental diseases;&#xD;
&#xD;
         20. The patient participated in another investigational device or drug study within 3&#xD;
             months;&#xD;
&#xD;
         21. Inapplicable for intravascular stenting treatment as per investigators judgment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhongrong Miao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 29, 2015</study_first_submitted>
  <study_first_submitted_qc>October 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2015</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic Stroke</keyword>
  <keyword>Intracranial Stenting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

